Health
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), addressing a critical concern for clinicians treating a disease with historically limited and poorly tolerated options.New subgroup analyses — including the first dedicated Japanese MASH population data and women in menopause — show semaglutide's benefits extend broadly, underscoring its potential to serve the full, diverse sp
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), addressing a critical concern for clinicians treating a disease with historically limited and poorly tolerated options.","length":295,"tagName":"p"}]},{"val":[{"type":"text","content":"New subgroup analyses — including the first dedicated Japanese MASH population data and women in menopause — show semaglutide's benefits extend broadly, underscoring its potential to serve the full, diverse spectrum of patients living with this silent epidemic, with nine out of 10 cases undiagnosed globally.","length":313,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-world evidence presented at EASL Congress 2026 reveals the devastating and largely hidden challenge of MASH: significant impairment in quality of life, soaring healthcare costs, and a patient population that remains critically underdiagnosed and undertreated.","length":264,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":872,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 19 May 2026 – At the European Association for the Study of the Liver (EASL) Annual Congress 2026 on 27-30 May in Barcelona, Spain, Novo Nordisk is presenting a comprehensive portfolio of new data highlighting a long-overdue spotlight on metabolic dysfunction-associated steatohepatitis — better known as MASH — a progressive and potentially fatal liver disease that affects an estimated 250 million people globally, yet remains widely unrecognised, un...